You’ll notice something that would have seemed improbable five years ago if you walk into practically any pharmacy in the US or the UK today. There’s a new resident in the refrigerated area. The tiny, stylish injector devices that have emerged as one of the most talked-about medical products of this decade sit alongside insulin pens and allergy shots. Wegovy. Mounjaro. Ozempic. The names have become commonplace abbreviations for a specific type of promise: the notion that a weekly injection can accomplish what years of dieting were unable to.
And it really does work for a lot of people. The burden is lifted. Semaglutide users lost an average of 15% of their body weight in clinical trials; in some cases, tirzepatide increased that percentage to 20%. In the past, bariatric surgery was necessary to reach those numbers. The enthusiasm among obesity medicine experts and endocrinologists has been genuine and, for the most part, warranted. Being overweight increases the risk of diabetes, heart disease, and some types of cancer. It matters to get it off.
Alongside the headlines about Novo Nordisk’s rising stock price and shrinking waistlines, however, there is a more subdued discussion taking place. It’s the discussion of the true effects these drugs have on the body and what happens when you stop using them.
Begin with the gut. GLP-1 agonists produce a prolonged feeling of fullness by slowing the rate at which food exits the stomach. Although that mechanism works well, it is not always comfortable to live with. Among the most frequently reported side effects are nausea, vomiting, constipation, and severe bloating; not everyone who experiences these side effects finds them to be minor annoyances. Ten to sixteen percent of users quit taking these drugs early because the gastrointestinal side effects are too severe. It’s worthwhile to sit with that significant number of people.
And there’s the vision problem, which has gotten far less public attention than it merits. Semaglutide use has been linked to a rare optic nerve condition known as NAION, or non-arteritic anterior ischemic optic neuropathy, according to research published in late 2025 that looked at data from the FDA’s adverse event reporting system. One eye may experience an abrupt loss of vision due to the condition.
Rapid drops in blood glucose may have an impact on the blood supply to the front of the optic nerve. The precise number of users who are at risk is still unknown, and researchers are cautious to point out that correlation does not imply causation. However, the discovery is significant enough to warrant not being buried in a footnote.
Another topic that is frequently overlooked in marketing discussions is muscle loss. Lean muscle and fat tissue are not clearly distinguished by rapid weight loss. Both are being lost by GLP-1 medication users, and bone density is also a growing concern. That is not a negligible trade-off, particularly for older adults. People may become physically weaker as a result of losing weight and muscle at the same time, which is an odd consequence for a medication marketed primarily as a health intervention.
The psychological aspect of all this may be the most underreported. Semaglutide use has been linked to mood swings, including anxiety and, in certain situations, suicidal thoughts. This relationship is disputed but enduring. The medications lessen cravings for high-fat and sugary foods by interfering with the dopamine and serotonin pathways in the brain. Although that mechanism aids in appetite, interfering with the brain’s reward chemistry can have unpredictable effects.
Swansea University researchers examined FDA adverse event data and discovered a connection between semaglutide and self-harm reports, but they did not establish a direct causal relationship. Firm conclusions cannot yet be drawn from the data. However, it is worthwhile to name the uncertainty itself.
The rebound follows. This information is arguably the most glaringly missing from the public discourse surrounding these drugs. Because GLP-1 drugs are expensive, have long-lasting side effects, and are still not widely available, about 65% of people stop taking them within a year. The weight returns when people stop. Research indicates that within a year of stopping, over 65% of the weight lost is regained. The medications successfully reduce appetite, but they don’t deal with the underlying biology or behaviors that initially caused the weight gain. That is not a small disclaimer. It’s a basic restriction.
This also has a social component, which researchers have only lately started to formally examine. According to a 2026 study, people who use GLP-1 medications to lose weight experience a different kind of social judgment that is, in some cases, harsher than that experienced by people who stay overweight or who lose weight through diet and exercise. The idea of the “easy way out” is still prevalent. Being judged for being heavy and then for how you became lighter is an odd double bind. The cruelty in that specific loop is difficult to ignore.
All of this does not imply that these medications are worthless. The advantages can be significant and well-established for those with severe obesity-related medical conditions. Over a nearly four-year follow-up period, a large 2025 study revealed that GLP-1 users had significantly lower risks of heart failure, cardiac arrest, and even Alzheimer’s disease. The image is actually quite intricate. However, the version of this story that is most widely publicized—transformation photos, celebrity endorsements, and skyrocketing pharmaceutical valuations—tends to ignore the complex details. It’s important to pay attention to that.
